BioAge Labs vs Emulate
Side-by-side comparison of AI visibility scores, market position, and capabilities
Clinical-stage biotech targeting metabolic aging for obesity and muscle-wasting disorders. IPO Sep 2024 (Nasdaq: BIOA); $198M raised; lead program azelaprag discontinued; pivoting to NLRP3 inhibitors.
About
BioAge Labs is a clinical-stage biopharmaceutical company that harnesses the biology of human aging to discover novel targets and therapies for metabolic diseases. The company went public on the Nasdaq Global Select Market in September 2024 under the ticker BIOA, raising $198M. Its lead program, azelaprag — an oral APJ agonist — was discontinued in January 2025 after the Phase 2 STRIDES obesity trial observed liver transaminitis in a subset of patients. BioAge has since pivoted its APJ program to next-generation oral and parenteral agonists targeting 2026 IND submissions, while advancing BGE-102, a brain-penetrant NLRP3 inhibitor development candidate with potential best-in-class CNS and metabolic applications. The company continues to leverage its proprietary human aging database to identify and validate novel drug targets.
Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.
About
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.